Clark Kensinger
Transplant Surgery · Atlanta, GANPI 1265759963
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $26,317 of the $34,991 with a category attached, or 75.2%. Organox Ltd accounts for 63.3% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $26,924, more than ten times the $17 reported in 2019.
Across 64 payments — averaging $546.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organox Ltd$22K
- Paragonix Technologies, Inc.$5K
- La Jolla Pharmaceutical Company$4K
- Intuitive Surgical$3K
- Sanofi-aventis U.S. LLC$154
- Boston Scientific$152
- plus $652 from 17 others
Across 2 payments — averaging $4500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Paragonix Technologies, Inc.$9K
What the payments were for
- Speaking & faculty fees$26,31775%
- Travel & lodging$3,1639%
- Food & beverage$2,5037%
- Education$3,0089%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organox Ltd | 16 | $22,144 |
| Paragonix Technologies, Inc. | 9 | $4,598 |
| La Jolla Pharmaceutical Company | 1 | $4,240 |
| Intuitive Surgical | 4 | $3,051 |
| Sanofi-aventis U.S. LLC | 3 | $154 |
| Boston Scientific | 1 | $152 |
| Fujifilm Healthcare Americas Corporation | 1 | $125 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $94 |
| Intercept Pharmaceuticals, Inc. | 5 | $89 |
| Veloxis Pharmaceuticals, Inc. | 2 | $57 |
| Orphalan Inc | 2 | $44 |
| AstraZeneca | 1 | $34 |
| Conmed Corporation | 2 | $29 |
| Mirum Pharmaceuticals, Inc. | 1 | $25 |
| AbbVie | 1 | $24 |
| Calliditas Therapeutics US Inc. | 1 | $23 |
| Madrigal Pharmaceuticals | 1 | $23 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Invivyd Inc | 1 | $20 |
| Vifor Pharma, Inc. | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $13 |
| Lemaitre Vascular, Inc. | 1 | $8 |
| Travere Therapeutics, Inc. | 3 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- METRA$21,801
- GIAPREZA$4,240
- Da Vinci Surgical System$3,000
- KidneyVault$1,500
- TheraSphere Y90 Glass Microspheres 10 GBq$152
- uTASWako AFP-L3$125
How this compares
$34,991 in reported general payments places this provider in the 80th percentile of 29 transplant surgery providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other transplant surgery in Atlanta
- Nicole TurgeonAtlanta$130K
- Stuart KnechtleAtlanta$88K
- Allan KirkAtlanta$80K
- Andrew AdamsAtlanta$60K
- Evan WeitmanAtlanta$40K
- Juliano RiellaAtlanta$15K
- Harrison PollingerAtlanta$9K
- Marty SellersAtlanta$4K
- Jonathan HundleyAtlanta$4K
- Steven KimAtlanta$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.